Pfizer's new generation of specific migraine treatment drug, Loctite, has been approved in China
芊芊551
发表于 2024-1-26 14:30:53
235
0
0
Pfizer announced on January 26th that its new generation of specific migraine treatment drug, Letaike (Rimezepam orally disintegrating tablets), has been approved by the National Medical Products Administration for the acute treatment of migraines in adults with or without aura.
According to Pfizer, this product is a calcitonin gene related peptide (CGRP) receptor antagonist using orally disintegrating tablet technology, which can effectively block the key pathways related to migraine onset, quickly and continuously alleviate headaches and related accompanying symptoms, and has no contraindications to cardiovascular diseases.
Jean Christophe Pointeau, Senior Vice President of Pfizer Global and President of Pfizer China, stated that Remdesipam Orally Invasive Tablets is the first next-generation migraine specific treatment drug to enter China. With CGRP as the treatment target and innovative Orally Invasive Technology, it solves the problem of insufficient drug efficacy and safety in the field of migraine treatment in the past.
"As the only CGRP receptor antagonist orally disintegrating tablets in the world to date, Rimezepam orally disintegrating tablets have brought new breakthroughs in the treatment of migraines, bringing new treatment options for Chinese clinical doctors and patients," he introduced.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- The number of infected cases has surged! US FDA approves Pfizer and Modena's updated COVID-19 vaccine
- Pfizer launches drug sales platform directly targeting American patients
- The Phase II clinical trial of Pfizer Ponsegromab in the treatment of cancer cachexia has reached its primary endpoint
- Pfizer and Shangyao Holdings have reached a strategic cooperation to jointly create a new format of high-quality preventive immunization services
- Pfizer CEO may meet with key executives of radical investor Starboard Value next week
- The first weekly long-acting hemophilia therapy has been approved by the FDA from Pfizer
- Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
- Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
-
2024年11月7日,由新华社新闻信息中心、新华社上海分社、新华社品牌工作办公室主办的“品牌·让世界更美好”中外品牌论坛在上海举办。此次论坛,理想汽车荣获“通用ESG企业评价规范”年度最佳品牌奖。理想汽车将 ...
- cool88817
- 昨天 19:20
- 支持
- 反对
- 回复
- 收藏
-
【别跟我提特朗普!鲍威尔发布会:无需过度解读措辞改变 民众“不觉得经济好”没错】北京时间周五凌晨3点30分,美联储主席鲍威尔举行新闻发布会,就继续降息25个基点的决定和市场热点话题回答全球媒体提问。鲍威尔在 ...
- anhao007
- 昨天 22:48
- 支持
- 反对
- 回复
- 收藏
-
何思文表示,“在进博会这个平台上,我们开启的是倾听模式,通过进博会展出各类产品,收集消费者的需求和反馈,进而帮助决定未来进口到中国的产品。过去,汽车行业的许多创新源于美国加州或欧洲。我相信,中国正 ...
- MaxLucky
- 昨天 12:44
- 支持
- 反对
- 回复
- 收藏
-
11月5日至10日,第七届中国国际进口博览会(下称“进博会”)在国家会展中心(上海)举办。在进博会期间,平安健康医疗科技有限公司(下称“平安健康”)与美敦力(上海)管理有限公司(下称“美敦力”)达成战 ...
- Hidden2
- 3 天前
- 支持
- 反对
- 回复
- 收藏